AG
PPBT

Advisor Group’s Purple Biotech PPBT Stock Holding History

Advisor Group’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Hold
0
– -$1K – 5015
2018
Q1 		– Sell
-1
Closed -$5.04K – 4837
2017
Q4 		$3K Hold
1
– – ﹤0.01% 4583
2017
Q3 		$2K Sell
1
-8
-89% -$29.8K ﹤0.01% 4562
2017
Q2 		$27K Sell
9
-1
-10% -$3.64K ﹤0.01% 3292
2017
Q1 		$39K Sell
10
-28
-74% -$134K ﹤0.01% 2911
2016
Q4 		$239K Buy
38
+34
+850% +$237K 0.01% 1440
2016
Q3 		$26K Buy
+4
New +$24.9K ﹤0.01% 2990

Other funds holding PPBT

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Advisor Group's PPBT Position: Q2 2018 in Review

Advisor Group held its Purple Biotech (PPBT) position steady in Q2 2018 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5015.

Advisor Group first reported a position in PPBT in Q3 2016 and has held it in 6 quarters since. The position peaked at $239K in Q4 2016. 5 funds tracked by Wall St. Rank hold PPBT as of Q2 2018.

  • Advisor Group held 0 shares of Purple Biotech worth $0 as of Q2 2018.
  • Advisor Group left its Purple Biotech share count unchanged in Q2 2018.
  • Purple Biotech made up ﹤0.01% of Advisor Group's portfolio in Q2 2018, its #5015 holding.
  • Advisor Group first reported a position in Purple Biotech in Q3 2016 and has held it in 6 quarters since.
  • Advisor Group's Purple Biotech position peaked at $239K in Q4 2016.
  • 5 funds tracked by Wall St. Rank held Purple Biotech as of Q2 2018.

Based on Advisor Group's 13F filing for Q2 2018, filed 13 Aug 2018.